Authorized purpose: Coronary plaque and stenosis quantification from CCTA
Clinical role
Measurement, quantification and diagnostic support
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: Qualified clinician review and analyst correction are required. Interpolated views may appear healthy where pathology is near or below scanning resolution.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Coronary plaque and stenosis quantification from CCTA
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: CCTA DICOM acquired on CT systems with at least 64 detector rows
Who uses it?Intended users: Qualified clinicians and trained analysts/operators
What does the software produce?Output: Vessel/lumen/wall segmentations; total, calcified, non-calcified and low-density plaque volumes/burden; stenosis measures; CAD-RADS category; Cardisight Overview and Plaque Analysis reports
What is its most important limitation?Key limitation: Qualified clinician review and analyst correction are required. Interpolated views may appear healthy where pathology is near or below scanning resolution.
Clinical takeaway. Clinical role: Coronary plaque and stenosis quantification from CCTA
Evidence takeaway. Evidence from the reviewed source record: Standalone study used 147 CCTA cases from three US sites with three-expert consensus reference; it did not use IVUS or histology as reference.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Coronary plaque and stenosis quantification from CCTA
Qualified clinician review and analyst correction are required. Interpolated views may appear healthy where pathology is near or below scanning resolution.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Standalone study used 147 CCTA cases from three US sites with three-expert consensus reference; it did not use IVUS or histology as reference.
No clinically interpretable sensitivity estimate was established in the reviewed summary.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
No clinically interpretable specificity estimate was established in the reviewed summary.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K260497 CCTA plaque/stenosis study
DesignStandalone expert-reference comparison
PopulationCCTA cases from three US sites
Scopeexact submission
Tested versionDEEPVESSEL Plaque in K260497
Samplen=147
Sites3
IndependenceIndependence not established
K260497
Reference is three-expert consensus, not IVUS or histology.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
Medicare local coverage policy L39881 (Noridian, MAC jurisdictions J-E and J-F) covers AI-enabled coronary plaque analysis from an already completed and interpreted CCTA for stable or acute chest pain with no known coronary disease when the CCTA is intermediate risk or CAD-RADS 1 to 3 and acute coronary syndrome evaluation is negative or inconclusive. It requires FDA cleared or approved software and does not name any product. The related billing article lists CPT 75577 (added effective 2026-01-01, replacing Category III codes 0623T-0626T). This is a regional service-level policy, not a determination that this exact product, version, site or claim is covered or paid. No payment amount was reviewed.
Service-level local coverage policy found (Noridian JE/JF LCD L39881); product-specific coverage and payment not established
Medicare (Noridian Healthcare Solutions MACs, jurisdictions J-E and J-F) · Noridian JE and JF states (California, Nevada, Hawaii, American Samoa, Guam, Northern Mariana Islands, Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming); other MAC jurisdictions not reviewed · Effective 2026-01-01
Code effective date comes from the billing article revision. LCD requires FDA cleared or approved software but names no product. Does not prove eligibility for a particular product version, patient, indication, site or claim; no payment amount reviewed.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CCTA DICOM acquired on CT systems with at least 64 detector rows
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-06Last searched
20Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored PubMed and clinical-trial candidate arrays are empty and were screened. No study was fabricated from vendor validation material. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, trial registry, recall database, payer policy, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
No public exact-version rate or procurement award reviewed.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not verified - checked 2026-09-05 - Exact FDA submission
Hosting region, retention, supported PACS interfaces and purchased configuration were not established.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
No dated, scoped security attestation reviewed.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Analyst credentialing, correction workflow and cardiologist review protocol require confirmation.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Reanalysis turnaround and analyst correction audit processes need local confirmation.
Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.
Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
Authorized purpose: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.